ibritumomab tiuxetan

Home
Ligands
ibritumomab tiuxetan

GtoPdb Ligand ID: 6777

Synonyms: IDEC-2B8 | IDEC-Y2B8-yttrium ibritumomab tiuxetan | NSC-715848 | Zevalin®

ibritumomab tiuxetan is an approved drug (FDA (2002), EMA (2004))

Compound class: Antibody

Comment: A monoclonal antibody used as a radioimmunotherapy treatment.

Summary
Biological activity
Clinical data
References
Immunopharmacology

No information available.

No information available.

Summary of Clinical Use
Used to treat relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma (labelled with the high energy beta emitter, Yttrium-90). Can be labelled with Indium-111 for diagnostic investigation/imaging.

Summary of Clinical Use

Used to treat relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma (labelled with the high energy beta emitter, Yttrium-90). Can be labelled with Indium-111 for diagnostic investigation/imaging.

Mechanism Of Action and Pharmacodynamic Effects
Yttrium-90 conjugated anti-CD20 monoclonal antibody. Once bound to CD-20 +ve B-cells of the lymphoma, the beta particles act locally to destroy the cancerous cells.

Mechanism Of Action and Pharmacodynamic Effects

Yttrium-90 conjugated anti-CD20 monoclonal antibody. Once bound to CD-20 +ve B-cells of the lymphoma, the beta particles act locally to destroy the cancerous cells.

External links
For extended ADME data see the following: Drugs.com European Medicines Agency (EMA)

External links

For extended ADME data see the following:

Drugs.com
European Medicines Agency (EMA)